Latest research on Imatinib

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

Imatinib and alcohol

Although Gleevec itself has no proven application in alcohol-based research, its SIDMAP analyses illustrate how metabolic flux in several pathways known to be affected by alcohol abuse can be measured simultaneously. [source, 2008]
Exclusion criteria included (1) local chemotherapy with intracavity instillation of cytotoxic agents, (2) cancer treatment with small molecule kinase inhibitor targeted therapy (e.g., Imatinib, sorafenib) or hormone therapy alone, (3) drug or alcohol related hepatitis, and (4) patients with positive results of serum anti-HCV antibody. [source, 2015]
When comparing adherent with non-adherent patients, in the univariate analysis, chi-squared test was used to analyze categorical data (gender, use of tobacco/smoking, use of alcohol, employment status, educational qualifications, patient educational sessions, financial assistance in treatment, Side effects of Imatinib, prevalence of depression, concomitant drug burden, polypharmacy, dose of Imatinib and frequency of dosing of Imatinib), the independent t-test was used to compare means (age, knowledge about medicine and disease, social support, physician patient interaction and duration of prescription of Imatinib) and Mann-Whitney U test was used to compare Monthly income. [source, 2015]
The variables included in the study were age, knowledge about medicine and treatment, physician patient interaction, those who attended patient educational sessions, male, depressed patients, smokers, alcoholics, educational qualifications, employed patients, patients who had side effects, being financially assisted in treatment, had concomitant drug burden, having polypharmacy and dosage of Imatinib. [source, 2015]
Tablets containing 400 mg of Imatinib mesylate were prepared by the wet granulation method using isopropyl alcohol as a granulating agent [22]. [source, 2015]
Drug Interactions: alcohol, Alitretinoin, Alprazolam, Amphotericin B, anticoagulants, atazanavir, benzodiazepines, cimetidine, Clopidogrel, Colchicine, Cyclosporine, erythromycin, Imatinib, Lopinavir, Methylprednisolone, Midazolam, Nevirapine, omeprazole, Pimecrolimus, prednisolone, Prednisone, Rifampin, Ritonavir, saquinavir, sildenafil, Simvastatin, Tacrolimus, Tramadol, triamcinolone, Vardenafil, vemurafenib. [source, 2013]